“Patients treated with the venetoclax-obinutuzumab combination showed a statistically significant sustained prolongation of PFS compared with patients treated with chlorambucil-obinutuzumab (76. ...
Hosted on MSN1mon
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary GoalsRHHBY’s Plans Forward for Gazyva/Gazyvaro to Treat Lupus Roche is currently gearing up to discuss the late-stage REGENCY study data with regulatory authorities in the United States and EU. LN is ...
The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...
Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...
Roche’s recent Phase III REGENCY trial results for Gazyva (obinutuzumab) suggest the therapy could directly address these needs. Gazyva, a CD20-directed cytolytic antibody, met its primary endpoint by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback